Doug Reed, PhD

Doug Reed Associate Professor
9043 BST3
3501 Fifth Avenue
Pittsburgh, Pennsylvania 15261

  Curriculum Vitae
  PubMed Publications
  Google Scholar

Phone: (412)648-9290
Fax: (412)648-8917
Lab Information

Phone: (412) 648-1922
Lab Members:
      • Bowling, Jennifer Dianne
      • CVR - RBLDSI
      • Ma, Henry
      • McAdams, Jaime
      • Midgett, Morgan L
      • Paranjpe, Tejas
      • Reed, Douglas S
      • Willett, Katherine Jean
      • Yaramati, Satya


      Dr. Reed did his doctoral work at the University of Texas Southwestern Medical Center at Dallas, working on thymocyte development in vitro. In 1995 Dr. Reed completed his dissertation and moved to Connecticut, where he worked as a postdoctoral fellow in the laboratory of Dr. Leo Lefrancois studying T lymphocyte activation in response to antigens entering through the small intestine. Dr. Reed became a principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in 1999, developing animal models to aerosolized pathogens and testing medical countermeasures in those models. While at USAMRIID Dr. Reed conducted and supervised aerosol exposures of animals including rodents, rabbits, and nonhuman primates. Dr. Reedís research at USAMRIID included developing nonhuman primate models of aerosol exposure to Venezuelan, Western, and Eastern Equine Encephalitis and evaluating candidate vaccines in those models, developing rodent and nonhuman primate (NHP) models of aerosol exposure to Marburg and Ebola viruses, and evaluating a GMP-grade recombinant plague vaccine in mice against pneumonic plague. In 2008 Dr. Reed moved to University of Pittsburgh to work in the Regional Biocontainment Laboratory. At Pittsburgh he has developed a rabbit model of pneumonic tularemia and is using that model to evaluate new vaccines and determine immunological correlates of protection. In collaboration with Dr. Amy Hartman he has developed the first reproducibly lethal NHP models of Rift Valley Fever and with Dr. Kate Ryman and Dr. William Klimstra is continuing his work on the encephalitic alphaviruses.



My research is focused on three primary areas: 1) the immune response to tularemia; 2) the role of the immune response in viral encephalitis; and 3) respiratory infection of animals with infectious agents. Francisella tularensis, a gram negative coccobacillus, is the causative agent of tularemia. In humans it has been shown that as few as 15 organisms can cause disease and pneumonic tularemia has a 30% mortality rate if untreated. There is concern that F. tularensis could be used as a biological weapon so vaccine and antibiotics that can treat tularemia are urgently needed. In my laboratory we have developed a rabbit model of pneumonic tularemia. In collaboration with Dr. Eileen Barry of the University of Maryland we have used this rabbit model to demonstrate that mutants of virulent F. tularensis that lack genes in key biosynthesis pathways are attenuated and efficacious against aerosol challenge with virulent F. tularensis. In addition to advancing those candidates towards clinical trials we are actively exploring the immune mechanisms that are important for protection.

In collaboration with Dr. Kate Ryman, Dr. William Klimstra and Dr. Amy Hartman we are working on animal models of viral encephalitis including Venezuelan Equine Encephalitis, Western Equine Encephalitis, Eastern Equine Encephalitis, and Rift Valley Fever virus. The pathogenesis seen in these infections are remarkably similar in rodent and nonhuman primate models suggesting similar mechanisms that are responsible for determining the outcome. We are actively exploring development of new nonhuman primate models and evaluation of potential medical countermeasures (vaccines and therapeutics) for the treatment or prevention of these diseases.

The Regional Biocontainment Laboratory in the BST3 has an Aerobiology suite capable of exposing animals to aerosols containing pathogenic viruses, bacteria and toxins. Aerosols are performed inside a class III biological safety cabinet inside the suite and can accommodate both BSL-2 and BSL-3 pathogens. We use a state-of-the-art computer controlled aerosol management platform, the AeroMP that was developed at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and that now is licensed and sold by Biaera Technologies (Hagerstown, MD). This system can accommodate a number of exposure chambers, aerosol generators and aerosol sampling devices. The flexibility of the AeroMP system allows for exposure of a wide variety of species including rodents, ferrets, rabbits, and nonhuman primates. We are one of only a few facilities in the world that has exposed marmosets to aerosolized pathogens.

Selected Publications

  • Stinson. E., Smith, L.P., Cole. K.S., Barry, E.M., Reed, D.S. In Press. Respiratory and oral vaccination improves protection conferred by the Live Vaccine Strain against pneumonic tularemia in the rabbit model. Pathog. Dis.

  • Cadena, A.M., Klein, E., White, A.G., Tomko, J., Reed, D.S., Chedrick, C.L., Via, L.E,. Lin, P.L., Flynn, J.L. In Press. Very low dose infection with Mycobacterium tuberculosis results in a spectrum of host outcomes in the common marmoset (Callithrix jacchus). Comp. Med.

  • Abdelbaqi, S., Deslouches, B., Steckbeck, J., Montelaro, R., Reed, D.S. 2016. Novel engineered cationic antimicrobial peptides have a broad-spectrum activity against Francisella tularensis, Yersinia pestis, and Burkholderia pseudomallei. J. Med Microbiol. 65(2):188-94 PMID: 26673248

  • Caroline, A.C., Kujawa, M.R, Oury, T., Reed, D.S., Hartman, A.L. 2016. Inflammatory biomarkers associated with lethal Rift Valley fever encephalitis in the Lewis rat model. Front Microbiol Immunol. 6:1509 doi: 10.3389/fmicb.2015.01509 PMID: 26779164

  • Reed, D.S.*, Glass, P.J.*, Bakken, R.R., Barth, J.F., Lind, C.M., Hart, M.K., Rayner, J., Alterson, K., Custer, M., Dudek, J., Owens, G., Kamrud, K.I., Parker, M.D., Smith, J. 2014. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitic viruses. J. Virol. 88(20):12077-86 PMID: 25122801 *- equal contribution

  • Reed, D.S., Smith, L., Cole, K.S., Santiago, A.E., Mann, B.J., Barry, E.M. 2014. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Infect Immun 82(5):2098-2105 PMID: 24614653

  • Caroline, A.L., Powell, D.S., Bethel, L.M., Oury, T.D., Reed, D.S., Hartman, A.L. 2014. Broad spectrum antiviral activity of Favipiravir (T-705): Protection from highly lethal inhalational Rift Valley Fever in Wistar-Furth rats. PLoS Negl Trop Dis 8(4):e2790 PMID: 24722586

  • Hartman, A.L., Powell, D.S., Bethel, L.M., Caroline, A.L., Schmid, R.J., Oury, T., Reed, D.S. 2014. Aerosolized Rift Valley Fever virus causes fatal encephalitis in African green monkeys and common marmosets. J. Virol. 88(4):2235-2245. PMID: 24335307

  • Faith, S.A., Smith, L.P., Swatland, A.S., Reed, D.S. 2012. Growth conditions and environmental factors impact aerosolization but not virulence of Francisella tularensis infection in mice. Front Cell Inf Microbio. 2(126):1-10. PMID: 23087911

  • Reed, D.S., Smith, L., Dunsmore, T., Trichel, A., Ortiz, L.A., Cole, K.S., Barry, E. 2011. Pneumonic tularemia in rabbits resembles the human disease as illustrated by radiographic and hematological changes after infection. PLoS One. 6(9):1-9. PMID: 21931798

Copyright © 2016 Center for Vaccine Research
Last Modified: Tuesday, July 16, 2013 at 1:15:38 PM
Disclosure Statement   •   Sitemap   •   Contact Us